## Mark D M Leiserson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2890340/publications.pdf

Version: 2024-02-01

24 papers 5,737 citations

14 h-index

623574

610775 24 g-index

26 all docs

 $\begin{array}{c} 26 \\ \text{docs citations} \end{array}$ 

26 times ranked 12908 citing authors

#	Article	IF	CITATIONS
1	<scp>ScalpelSig</scp> Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures. Journal of Computational Biology, 2022, 29, 56-73.	0.8	1
2	SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types. Cell Genomics, 2022, 2, 100099.	3.0	2
3	Mutational Signatures: From Methods to Mechanisms. Annual Review of Biomedical Data Science, 2021, 4, 189-206.	2.8	19
4	A data-driven approach for constructing mutation categories for mutational signature analysis. PLoS Computational Biology, 2021, 17, e1009542.	1.5	1
5	A mixture model for signature discovery from sparse mutation data. Genome Medicine, 2021, 13, 173.	3.6	8
6	A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nature Communications, 2021, 12, 6512.	5.8	24
7	Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer. Genome Medicine, 2020, 12, 52.	3.6	20
8	A Sticky Multinomial Mixture Model of Strand-Coordinated Mutational Processes in Cancer. IScience, 2020, 23, 100900.	1.9	5
9	Matrix (factorization) reloaded: flexible methods for imputing genetic interactions with cross-species and side information. Bioinformatics, 2020, 36, i866-i874.	1.8	1
10	Hidden Markov models lead to higher resolution maps of mutation signature activity in cancer. Genome Medicine, 2019, 11, 49.	3.6	22
11	Modeling clinical and molecular covariates of mutational process activity in cancer. Bioinformatics, 2019, 35, i492-i500.	1.8	15
12	Functional protein representations from biological networks enable diverse cross-species inference. Nucleic Acids Research, 2019, 47, e51-e51.	6.5	23
13	Criticality in tumor evolution and clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11101-E11110.	3.3	23
14	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. PLoS ONE, 2018, 13, e0208422.	1.1	14
15	Hierarchical HotNet: identifying hierarchies of altered subnetworks. Bioinformatics, 2018, 34, i972-i980.	1.8	102
16	Precision Oncology: The Road Ahead. Trends in Molecular Medicine, 2017, 23, 874-898.	3.5	131
17	Reply: Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nature Genetics, 2016, 48, 106-108.	9.4	2
18	CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biology, 2015, 16, 160.	3.8	182

#	Article	IF	CITATIONS
19	MAGI: visualization and collaborative annotation of genomic aberrations. Nature Methods, 2015, 12, 483-484.	9.0	25
20	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	5.8	243
21	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics, 2015, 47, 106-114.	9.4	830
22	Integrated analysis of germline and somatic variants in ovarian cancer. Nature Communications, 2014, 5, 3156.	5.8	253
23	Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502, 333-339.	13.7	3,695
24	Network analysis of GWAS data. Current Opinion in Genetics and Development, 2013, 23, 602-610.	1.5	95